17q gain in neuroblastoma predicts adverse clinical outcome
| Autor: | Paul H. Roberts, Ian Lewis, Simon Cotterill, Nick Bown, Maria astowska, Caroline Ellershaw, Seamus O'Neill |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Univariate analysis Multivariate analysis business.industry Cytogenetics Chromosome Disease Bioinformatics medicine.disease Chromosome 17 (human) Internal medicine Neuroblastoma Pediatrics Perinatology and Child Health medicine Stage (cooking) business |
| Zdroj: | Medical and Pediatric Oncology. 36:14-19 |
| ISSN: | 1096-911X 0098-1532 |
| DOI: | 10.1002/1096-911x(20010101)36:1<14::aid-mpo1005>3.0.co;2-g |
| Popis: | Background It is now recognized that gain of chromosome 17 material is the most frequent genetic abnormality of neuroblastoma cells. Several studies have linked 17q gain with known adverse prognostic factors: patient age 1 year, 1p deletion, and MYCN amplification (all P < 0.01). In univariate analysis, 17q gain was a significant predictor of adverse outcome (projected 5 year relapse-free survival 15.6% compared to 75.2% in cases lacking this feature in tumour cells; (P < 0.0001). In multivariate analysis, 17q gain was more strongly associated with adverse outcome than was either stage (Stage 4 vs other combined) or 1p status. Conclusion We conclude that gain of chromosome segment 17q21-qter is of great biological and clinical importance in neuroblastoma, and that its detection at diagnosis should be a priority. Med. Pediatr. Oncol. 36:14–19, 2001. © 2001 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text